Workflow
Aerodynamic Separation Process
icon
Search documents
ASP Isotopes Inc. to host Institutional Investor Access Event in South Africa from November 11 – 13, 2025
Globenewswire· 2025-10-10 13:15
*** Limited places remain available for institutional investors for this previously announced Investor Access Event *** WASHINGTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it will host an Institutional Investor Access Event in South Africa from November 11-13, 2025. **There is als ...
ASP Isotopes Inc. Announces Changes to the Executive Management Teams of ASP Isotopes Inc. and Quantum Leap Energy LLC Effective October 2025
Globenewswire· 2025-09-29 12:00
Core Points - ASP Isotopes Inc. has appointed Robert Ainscow as Interim CEO while Paul Mann takes a temporary leave of absence for health reasons [1][3] - Michael Cunniffe has been appointed as CFO of Quantum Leap Energy LLC, effective October 1, 2025 [6][7] Company Leadership Changes - Paul Mann will transition to the role of Executive Chairman, focusing on overall leadership and strategic direction [2] - Robert Ainscow, co-founder and current COO, will manage CEO responsibilities and maintain key industry relationships during Mann's recovery [5][4] Health Update - Paul Mann underwent successful orthopedic surgery on September 19, 2025, but his recovery may take several months [3] Upcoming Investor Events - ASP Isotopes will host an Institutional Investor Access Event in South Africa on November 12 and 13, 2025 [9] - The company plans to provide quarterly business updates starting in November 2025 [11] Company Overview - ASP Isotopes Inc. focuses on developing technology for isotope production, particularly for healthcare and technology industries [12] - The company employs proprietary Aerodynamic Separation Process technology and has facilities in Pretoria, South Africa [12][13]
ASP Isotopes Inc. Announces Updates on the Progress of Commercial Production at its Three Enrichment Facilities in South Africa
Globenewswire· 2025-07-17 12:00
Core Insights - ASP Isotopes Inc. is advancing its commercial production of isotopes, particularly Silicon-28 and Ytterbium-176, with significant capacity expansions and operational updates [1][4]. Production Updates - Silicon-28 production commenced in late March 2025, achieving an enrichment level of 99% and expected to ship products enriched to at least 99.995% by August 2025. The annual capacity is now projected to exceed 80 kilograms, up from previous estimates of 50 kilograms and initial expectations of 10 kilograms, with a $4 million investment for capacity expansion [2]. - Ytterbium-176 production began in April 2025, reaching an enrichment factor of 52, with plans to ship commercial samples by August 2025. The production process is transitioning to a semi-continuous method to target a production rate of 1 kilogram per annum [3]. Equipment and Facility Developments - The company has received permits to import laser equipment for enriching Nickel-64, Gadolinium-160, and Zinc-68, and is accelerating plans for additional enrichment facilities in South Africa [5]. - The Carbon-14 enrichment plant faced delays due to insufficient feedstock but is now enriching Carbon-12 to 99.99%, with commercial supply expected in August 2025. Demand for Carbon-12 is significantly higher than for Carbon-14, prompting the company to consider expanding capacity [6][7]. Technological Advancements - The company utilizes the Aerodynamic Separation Process (ASP technology) for isotope enrichment, which is believed to offer a cost-effective and efficient method compared to traditional separation techniques [8]. Future Plans - The company plans to spin out its subsidiary Quantum Leap Enrichment in the second half of 2025, targeting October 2025 for completion, and anticipates closing the Renergen acquisition in the third quarter of 2025, pending regulatory approvals [9].